INVIO Pharmaceuticals Gets Grant To Produce COVID-19 Vaccine
One of the most important priorities facing the United States (and the world too) is finding a therapeutic and treatment for the coronavirus, and pharmaceutical and biotech companies all over the world are working against the clock to figure out a way to prevent or treat the spread of Coronavirus. One such company, INVIO, has been awarded a grant to help continue in this critical work.
INVIO’s hope is that they can produce over a million units of their proposed COVID-19 vaccine by the end of 2020, after receiving a grant from Oslo-based Coalition for Epidemic Preparedness Innovation.
This is not the first round of funding that CEPI has given to Invio, this grant actually brings the total round of funding to $17.2 million, which will be used by the company to expand manufacturing of it’s proposed COVID-19 vaccine. That vaccine is currently being worked on at Invio’s Plymouth, Pennsylvania location.
Should we be hopeful?
As the pandemic continues on, as contagious as it is, having an available vaccine becomes more and more necessary, especially considering there is currently no therapeutic approved to treat COVID-19 patients, which can be a scary thing for anyone with relatives or loved ones that have been infected.
According to a statement posted on INVIO’s website,
INOVIO scientists are coronavirus experts.INOVIO was the first to advance its DNA vaccine INO-4700 against MERS CoV, a related coronavirus, into evaluation in humans.INOVIO is currently preparing to initiate a Phase 2 vaccine trial for INO-4700 in the Middle East where most MERS viral outbreaks have occurred.
The company is expediting the development of INO-4800 against COVID-19 and is planning to have 1 million doses of the vaccine by the end of 2020.
If you are a research scientist in need of grant funding, start by doing a search in the Research and Evaluation category on GrantWatch. If your research is Coronavirus specific, the grants listed in the Coronavirus COVID-19 category
